Greffex Receives Notice from the National Eye Institute/NIH to Begin Gene Therapy Work on Usher Syndrome Blindness

In the fall of 2020, Greffex was awarded an NIH contract to develop a gene therapy to address Usher Syndrome blindness.  According to Greffex CEO, John Price, “Greffex is excited to continue its mission to provide hope to children and families who have been dealt a harsh hand.  Usher Syndrome affects both hearing and vision loss in children and young adults to varying degrees. It is a hereditary disease with no current cure, however, Greffex will deploy its gene therapy expertise in hopes of preventing the blindness aspect of Usher.” 

Chief Scientific Officer, Dr. Uwe Staerz, and his team in Aurora, Colorado will lead the studies which they will commence on March 1, 2021.

In addition to its work on Usher Syndrome, Greffex is continuing to accelerate its vaccine program, with two vaccine candidates in pre-clinical trials – a Covid-19 vaccine and an H5N1 avian influenza vaccine – and a third vaccine candidate for universal flu nearing pre-clinical stage later in 2021.